NEW YORK — In this video commentary from HemOnc Today New York, co-program chair Sanjiv S. Agarwala, MD, summarizes highlights from the melanoma session.
The session began with an overview of the basics of immunotherapy and side effect management.
Subsequent presentations focused on new data in adjuvant therapy of melanoma — including the roles of targeted therapy and immunotherapy in this setting — as well as whether new data that offers insights into whether patients should undergo completion lymphadenectomy is impacting the approach toward surgery and adjuvant treatment.
The session also included a discussion of treatment advances for metastatic disease, ongoing research efforts to make immunotherapy more effective and overcome resistance, and the potential for combining immunotherapy and targeted therapy.
“There were plenty of take-home points that clinicians can immediately apply to their practice, and hopefully this will be very useful information for them,” Agarwala told HemOnc Today.
Disclosure: Argawala reports no relevant financial disclosures.